|1.||Chemtob, Sylvain: 1 article (12/2004)|
|2.||Beauchamp, Martin H: 1 article (12/2004)|
|3.||Checchin, Daniella: 1 article (12/2004)|
|4.||Varma, Daya R: 1 article (12/2004)|
|5.||Hardy, Pierre: 1 article (12/2004)|
|6.||Speranza, Giovanna: 1 article (12/2004)|
|7.||Kermorvant-Duchemin, Elsa: 1 article (12/2004)|
|8.||Sennlaub, Florian: 1 article (12/2004)|
|9.||Abran, Daniel: 1 article (12/2004)|
|10.||Lachapelle, Pierre: 1 article (12/2004)|
|1.||Ehrlich Tumor Carcinoma
|2.||Body Weight (Weight, Body)
05/14/1993 - "The results showed a significant inhibition of tumor incidence by CuDIPS pretreatment during promotion-progression. "
07/01/1992 - "Activity of CuDIPS against mammary cancer in C3H HeNCR mice."
11/01/1991 - "CuDIPS, an inhibitor of tumor promotion, was an effective inhibitor of CL in all the protocols evaluated. "
04/01/1988 - "A keratinocyte-mediated mutagenesis assay, and the murine skin multistage carcinogenesis tumor model were used to survey the chemopreventive properties of Cu(II)(3,5-diisopropylsalicylate)2 [CuDIPS] and its analogs. "
01/01/1988 - "Maximal inhibitory effects on tumor incidence were achieved by CUDIPS concentrations of 0.35 mumol/mouse and 0.50 mumol/mouse. "
12/01/2004 - "CuDIPS, FeTPPS, and L-NA treatments for these 2 days of hyperoxia nearly abolished the vasoobliteration. "
01/01/1993 - "aeruginosa to hyperoxia nor supplementation with the antioxidants copper(II) (diisopropylsalicylate)2 (superoxide dismutase-like), catalase, or dimethyl sulfoxide abolished prolongation of the PAE of tobramycin induced by hyperoxia."
05/14/1993 - "There was a significant increase in the keratoacanthoma-papilloma ratio when the period of treatment with BzPo was prolonged, which was inhibited by CuDIPS pretreatment. "
04/01/1988 - "Topical pretreatment of SENCAR mice with CuDIPS (100-4000 nmol) 15 min prior to initiation with DMBA or BP resulted in small (38% maximum) non-dose-responsive reductions of papillomas/mouse following 20 weeks of promotion."
|8.||Butylated Hydroxytoluene (BHT)
|9.||Vitamin K 3 (Menadione)
|10.||Reactive Oxygen Species (Oxygen Radicals)